Allarity shareholders reject equity plan increase and officer exculpation

Allarity Therapeutics, Inc.

Thomas H. Jensen re-elected as Class III director with 1,673,698 for, 265,465 withheld.
Ratification of Wolf & Company as auditor passed with 6,706,148 votes for.
Proposal to increase 2021 Plan shares from 717,941 to 3,415,068 failed (928,978 for vs 932,866 against).
Amendment to limit officer liability (Officer Exculpation) also did not pass (1,359,331 for vs 563,585 against).
Adjournment proposal approved 4,976,159 for, 1,924,694 against; quorum was 41% of outstanding shares.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.